Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0210362643
Mon, 16.03.2026
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 16, 2026, 7am CET
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
US FDA [ … ]
Thu, 12.03.2026
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 12, 2026, 7am CET.
Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first patient dosed in Phase 2b trial within UNITE4TB, following completion of a Phase 2a in adults with drug-susceptible pulmonary TB (DS-TB) in combination with [ … ]
Wed, 04.03.2026
BioVersys AG
BioVersys AG
/ Key word(s): Scientific publication
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy 04.03.2026 / 07:00 CET/CEST
Basel, Switzerland. March 04, 2026, 7am CET
BV100 Phase 1, single- and multiple-ascending dose clinical trial data [ … ]
